Stock listing
TSX:MSCL Satellos Bioscience Inc Stock
Home listing (TSX) of Satellos Bioscience Inc
Follow Satellos Bioscience Inc into a list and get an email when it puts out news.
Share price · TSX:MSCL
$8.24 CAD -0.38 (-4.4%)
Close on Nov 20, 2026
- Day range
- $8.11 – $8.50 CADNov 20, 2026
- Volume
- 13,796 sharesNov 20, 2026
- Market cap
- $174.8M CADAt the close on Nov 20, 2026 · price × 21.22M shares outstanding
- 52-week range
- $7.56 – $18.98 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $139,697 CADMedian day 10,700 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSX:MSCL · Home | $8.24 CAD | -0.38 (-4.4%) | 13,796 | $8.50 | $8.50 | $8.11 | $8.62 | Close on Nov 20, 2026 |
| NASDAQ:MSLE | $5.68 USD | -0.12 (-2.1%) | 113,907 | $5.71 | $6.001 | $5.62 | $5.80 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSX:MSCL · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $8.24 | -0.38 | -4.4% | $8.50 | $8.50 | $8.11 | 13,796 | |
| $8.62 | -0.28 | -3.1% | $8.97 | $9.20 | $8.55 | 12,252 | |
| $8.90 | -0.29 | -3.2% | $9.05 | $9.10 | $8.75 | 28,972 | |
| $9.19 | -0.31 | -3.3% | $9.33 | $9.44 | $9.08 | 17,664 | |
| $9.50 | -0.07 | -0.7% | $10.24 | $10.24 | $9.28 | 6,491 | |
| $9.57 | -0.04 | -0.4% | $9.75 | $9.75 | $9.25 | 23,176 | |
| $9.61 | -0.34 | -3.4% | $9.88 | $10.00 | $9.61 | 5,762 | |
| $9.95 | -0.49 | -4.7% | $10.47 | $10.50 | $9.89 | 15,506 | |
| $10.44 | +0.32 | +3.2% | $10.15 | $10.51 | $9.99 | 12,328 | |
| $10.12 | +1.10 | +12.2% | $9.40 | $10.49 | $9.20 | 29,021 | |
| $9.02 | -0.29 | -3.1% | $9.08 | $9.08 | $8.65 | 34,191 | |
| $9.31 | +0.31 | +3.4% | $9.00 | $9.31 | $9.00 | 401 | |
| $9.00 | -0.05 | -0.6% | $9.08 | $9.11 | $9.00 | 7,819 | |
| $9.05 | -0.49 | -5.1% | $9.32 | $9.32 | $9.05 | 826 | |
| $9.54 | -0.06 | -0.6% | $9.60 | $9.60 | $9.05 | 3,137 | |
| $9.60 | +0.57 | +6.3% | $9.08 | $9.76 | $9.05 | 3,019 | |
| $9.03 | -0.64 | -6.6% | $9.67 | $9.88 | $9.01 | 13,760 | |
| $9.67 | +0.34 | +3.6% | $9.52 | $10.00 | $9.52 | 9,036 | |
| $9.33 | +0.20 | +2.2% | $9.25 | $9.33 | $9.00 | 11,145 | |
| $9.13 | +0.01 | +0.1% | $9.23 | $9.38 | $9.05 | 7,208 | |
| $9.12 | -0.40 | -4.2% | $9.39 | $9.68 | $9.12 | 17,700 | |
| $9.52 | -0.19 | -2.0% | $9.84 | $9.84 | $9.40 | 4,900 | |
| $9.71 | +0.53 | +5.8% | $9.37 | $9.71 | $9.27 | 9,300 | |
| $9.18 | -0.07 | -0.8% | $9.60 | $9.65 | $9.02 | 5,700 | |
| $9.25 | -0.54 | -5.5% | $10.00 | $10.00 | $9.25 | 13,200 | |
| $9.79 | +0.29 | +3.1% | $9.61 | $9.79 | $9.40 | 4,000 | |
| $9.50 | -0.40 | -4.0% | $10.01 | $10.01 | $9.48 | 6,100 | |
| $9.90 | -0.81 | -7.6% | $10.70 | $10.70 | $9.90 | 37,700 | |
| $10.71 | +0.29 | +2.8% | $10.50 | $11.10 | $10.34 | 12,200 | |
| $10.42 | -0.71 | -6.4% | $11.64 | $11.64 | $10.31 | 19,400 | |
| $11.13 | +0.36 | +3.3% | $10.75 | $11.83 | $10.56 | 10,100 | |
| $10.77 | -0.73 | -6.3% | $11.74 | $11.75 | $10.72 | 13,200 | |
| $11.50 | -0.51 | -4.2% | $12.47 | $12.47 | $11.50 | 9,400 | |
| $12.01 | -0.08 | -0.7% | $12.41 | $12.41 | $12.01 | 25,500 | |
| $12.09 | 0.00 | 0.0% | $12.02 | $12.50 | $12.02 | 4,400 | |
| $12.09 | -0.11 | -0.9% | $12.49 | $12.49 | $12.02 | 10,400 | |
| $12.20 | -0.26 | -2.1% | $12.29 | $12.42 | $12.02 | 14,500 | |
| $12.46 | -0.04 | -0.3% | $12.35 | $12.64 | $12.35 | 3,000 | |
| $12.50 | +0.16 | +1.3% | $12.20 | $12.51 | $12.17 | 1,700 | |
| $12.34 | +0.17 | +1.4% | $12.75 | $12.75 | $11.97 | 9,600 | |
| $12.17 | -0.51 | -4.0% | $12.50 | $12.50 | $12.01 | 17,500 | |
| $12.68 | -0.19 | -1.5% | $12.87 | $12.87 | $12.45 | 5,700 | |
| $12.87 | -0.16 | -1.2% | $13.10 | $13.10 | $12.87 | 12,400 | |
| $13.03 | -0.24 | -1.8% | $13.48 | $13.49 | $13.03 | 4,800 | |
| $13.27 | +0.27 | +2.1% | $13.34 | $13.50 | $13.27 | 13,600 | |
| $13.00 | -0.01 | -0.1% | $13.03 | $13.36 | $13.00 | 10,900 | |
| $13.01 | -0.50 | -3.7% | $13.13 | $13.15 | $13.01 | 5,900 | |
| $13.51 | +0.31 | +2.3% | $14.00 | $14.00 | $13.51 | 6,100 | |
| $13.20 | -0.73 | -5.2% | $13.99 | $14.16 | $13.20 | 7,100 | |
| $13.93 | +0.08 | +0.6% | $13.95 | $14.34 | $13.56 | 10,500 | |
| $13.85 | +1.08 | +8.5% | $12.94 | $14.25 | $12.89 | 22,500 | |
| $12.77 | +0.32 | +2.6% | $12.45 | $13.26 | $12.44 | 31,100 | |
| $12.45 | -0.08 | -0.6% | $12.35 | $12.62 | $12.35 | 1,100 | |
| $12.53 | -0.07 | -0.6% | $12.57 | $12.79 | $12.39 | 11,500 | |
| $12.60 | -0.25 | -1.9% | $12.41 | $12.66 | $12.41 | 8,600 | |
| $12.85 | -0.16 | -1.2% | $13.03 | $13.03 | $12.51 | 4,200 | |
| $13.01 | +0.90 | +7.4% | $12.95 | $13.01 | $12.14 | 29,600 | |
| $12.11 | -0.97 | -7.4% | $13.21 | $13.22 | $12.11 | 9,300 | |
| $13.08 | 0.00 | 0.0% | $13.00 | $13.10 | $12.97 | 9,800 | |
| $13.08 | +0.08 | +0.6% | $13.00 | $13.21 | $13.00 | 19,000 | |
| $13.00 | -0.29 | -2.2% | $13.29 | $13.68 | $13.00 | 12,700 | |
| $13.29 | -0.22 | -1.6% | $13.52 | $13.52 | $13.00 | 18,700 | |
| $13.51 | -0.30 | -2.2% | $13.70 | $13.81 | $13.40 | 17,900 | |
| $13.81 | -0.01 | -0.1% | $14.00 | $14.00 | $13.45 | 21,000 |
Splits
2 splits since 2021 · TSX:MSCL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-20 | Consolidation |
- Ticker
- TSX:MSCL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TSX
- Currency
- CAD
What changed lately
Latest news release · Nov 12, 2026
Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress
Latest deck · Nov 6, 2026
Corporate Update (November 2026)
Corporate update · 17 slides
Latest news
Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress
Nov 12, 2026
Closed $9.57 (-0.4%) on Nov 12, 2026
Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
Nov 6, 2026
Closed $10.12 (+12.2%) on Nov 6, 2026
Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
Nov 5, 2026
Closed $10.12 (+12.2%) on Nov 6, 2026
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
Oct 27, 2026
Closed $9.67 (+3.6%) on Oct 27, 2026
Satellos to Participate in Upcoming Investor Conferences
Oct 21, 2026
Closed $9.52 (-2.0%) on Oct 21, 2026
Satellos Granted Composition of Matter Patent for Forazapadin
Oct 5, 2026
Closed $11.50 (-4.2%) on Oct 5, 2026
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Sep 30, 2026
Closed $12.09 (-0.9%) on Sep 30, 2026
Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development
Sep 24, 2026
Closed $12.34 (+1.4%) on Sep 24, 2026
Satellos to Present at the 31st Annual Congress of the World Muscle Society
Sep 15, 2026
Closed $13.01 (-3.7%) on Sep 15, 2026
Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247
Sep 9, 2026
Closed $13.85 (+8.5%) on Sep 9, 2026
Satellos Bioscience Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 122 in all · newest Nov 12, 2026 · oldest 2021
- Decks
- 17 decks · latest Nov 6, 2026
Where Satellos Bioscience Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSX:MSCL · Home listing · This page | TSX | Canada | CAD |
| NASDAQ:MSLE | NASDAQ | United States | USD |
| Cboe Canada:MSCL | Cboe Canada | Canada | CAD |
| LS Exchange:A4211W | LS Exchange | Germany | EUR |
| Lang & Schwarz:A4211W | Lang & Schwarz | Germany | EUR |
| BOATS:MSLE | BOATS | United States | USD |
| Frankfurt:0IT | Frankfurt | Germany | EUR |
| Stuttgart:0IT | Stuttgart | Germany | EUR |
| Tradegate:0IT | Tradegate | Germany | EUR |
Valuation
Price/book 2.5× against a median of 1.7×: 7th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $99.28M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P/TSX Composite
- 0.49
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Satellos Bioscience Inc · TSX:MSCL | US$121.9M | US$69.23M | n/a | n/a | n/a | 2.5× | n/a | 0.0× | 0.49 |
| MacroGenics, Inc. · NASDAQ:MGNX | US$125.3M | −US$127.6M | n/a | −0.9× | n/a | 5.0× | −34.6% | 1.4× | 0.83 |
| PolyPid Ltd. · NASDAQ:PYPD | US$124.3M | US$119.3M | n/a | n/a | n/a | 23.1× | n/a | 0.3× | 0.93 |
| Compass Therapeutics, Inc. · NASDAQ:CMPX | US$123.9M | −US$29.89M | n/a | n/a | n/a | 0.9× | n/a | 0.1× | 1.22 |
| Humacyte, Inc. · NASDAQ:HUMA | US$123.7M | US$96.01M | n/a | 40.1× | n/a | 6.8× | n/a | 2.0× | 2.56 |
| Biomm SA · BMFBOVESPA:BIOM3 | US$122.6M | US$136.5M | 18.4× | 2.1× | 12.3× | 2.2× | 10.3% | 0.3× | n/a |
| Invivyd, Inc. · NASDAQ:IVVD | US$122.0M | US$3.86M | n/a | 0.1× | n/a | 0.8× | −214.8% | 0.1× | 2.06 |
| Alar Pharmaceuticals Inc · TPEX:6785 | US$121.0M | US$51.66M | n/a | 568× | n/a | 1.7× | n/a | 0.0× | n/a |
| CANbridge Pharmaceuticals Inc. · HKEX:1228 | US$120.4M | US$111.5M | n/a | 13.3× | n/a | n/a | −146.4% | n/a | n/a |
| Atrium Therapeutics, Inc. · NASDAQ:RNA | US$118.4M | −US$113.0M | n/a | −2.9× | n/a | 0.6× | −229.7% | 0.0× | 0.76 |
| Adagene, Inc. · NASDAQ:ADAG | US$118.2M | −US$3.65M | n/a | −0.5× | n/a | 1.1× | −229.6% | 0.1× | 1.43 |
| Median of the others | US$122.3M | US$27.76M | 18.4× | 1.1× | 12.3× | 1.7× | −180.6% | 0.1× | 1.22 |
Forecasts
Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.67 CAD · Analysts' mean
- EPS, year to Dec 2026
- -3.11 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Frank Gleeson | Co-founder, Chief Executive Officer, Board Director |
| Liz Williams | CFO |
| Caitlin Lowie | Vice President, Investor Relations & Communications |
| Antoinette Paone | Chief Development Officer and Head of Regulatory Affairs |
Board
| Director | Role |
|---|---|
| Geoff MacKay | Chair, BOD | Chair, Compensation Committee |
| Adam Mostafa | Director | Chair, Audit Committee |
| Brian Bloom | Director |
| Frank Gleeson | Co-founder, Chief Executive Officer, Board Director |
| Franklin M. Berger | Director |
| Iris Loew-Friedrich | Director |
| Mark Nawacki | Director |
| Selwyn Ho | Director |
| Stephanie Brown | Director | Chair, Nominations and Governance Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −0.4% |
| Q2 2026 | Aug 13, 2026 · After close | −3.4% |
| Q1 2026 | May 13, 2026 · Before open | −2.2% |
| Q4 2025 | Mar 27, 2026 · Before open | −10.3% |
| Q3 2025 | Nov 14, 2025 · Before open | +5.8% |
| Q2 2025 | Aug 13, 2025 · Before open | −8.3% |
| Q1 2025 | May 13, 2025 · Before open | +4.7% |
| Q4 2024 | Mar 26, 2025 | +2.6% |
| Q3 2024 | Nov 13, 2024 · Before open | +1.2% |
| Q2 2024 | Aug 12, 2024 · After close | +4.3% |
All 14 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · After close | 0.0% |
| Q4 2023 | Mar 27, 2024 · Before open | +4.3% |
| Q3 2023 | Nov 22, 2023 · After close | 0.0% |
| Q4 2022 | Mar 29, 2023 · After close | +24.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (November 2026) | Corporate update | 17 slides | Nov 6, 2026 |
| Corporate Update (July 2026) | Corporate update | 14 slides | Jul 8, 2026 |
| 2026 Bloom Burton & Co. Healthcare Investor Conference | Conference | 23 slides | April 2026 |
| Technical Presentation (February 2026) | Technical | 52 slides | Feb 24, 2026 |
| Investor Presentation (February 2026) | Investor deck | 21 slides | February 2026 |
| Investor Presentation (October 2025) | Investor deck | 19 slides | October 2025 |
| Investor Presentation (June 2025) | Investor deck | 22 slides | Jun 5, 2025 |
| CureDuchenne FUTURES National Conference 2025 | Conference | 11 slides | May 24, 2025 |
| 2025 Bloom Burton & Co. Healthcare Investor Conference | Conference | 26 slides | May 5, 2025 |
| 30th Annual PPMD Conference 2024 | Conference | 12 slides | Jun 29, 2024 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (February 2024) | Investor deck | 17 slides | February 2024 |
| Investor Presentation (February 2023) | Investor deck | 21 slides | February 2023 |
| Life Science Investor Forum 2022 | Conference | 17 slides | Jun 23, 2022 |
| Investor Day (March 2022) | Investor day | 16 slides | Mar 13, 2022 |
| Investor Presentation (February 2022) | Investor deck | 21 slides | Feb 22, 2022 |
| Market Radius (February 2022) | Conference | 19 slides | Feb 9, 2022 |
| Investor Presentation (December 2021) | Investor deck | 21 slides | December 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Public offering of common shares and pre-funded warrants Closed: US$57.2M raised · US$10.1 a share · Leerink Partners +4 Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Oppenheimer & Co. (co-lead), Bloom Burton, Bloom Burton Securities Inc. Buyers: Franklin Berger (24,750 common shares); Mark Nawacki (30,000 common shares) Insiders: Director Franklin Berger purchased 24,750 common shares; no other insiders participated. Use of proceeds: Research and development including SAT-3247 clinical trials, other discovery and pre-clinical programs, working capital and general corporate purposes | Feb 9, 2026 | |
| Warrant exercise of share purchase warrants Closed: C$1.04M raised | Sep 22, 2025 | US$754,560 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 25.0K | |||||
| Cost of revenue | 5.09K | 7.00K | 3.73M | 165.7K | 422 | 3.06K | 1.54K | 23.5K | 27.4K | |
| Gross profit | -5.09K | -8.82M | -3.73M | -165.7K | -422 | -3.06K | -1.54K | -23.5K | -27.4K | |
| Research and development | 18.4M | 14.4M | 8.82M | 2.59M | 1.88M | 892.8K | 917.5K | 1.42M | 786.6K | 564.2K |
| Selling, general and administrative | 7.44M | 6.06M | 4.66M | 1.13M | 182.4K | 857.4K | ||||
| Operating income | -26.5M | -20.4M | -15.5M | -8.43M | -6.65M | -2.77M | -2.21M | -2.20M | -1.47M | -1.23M |
| Depreciation and amortization | 4.00K | 15.0K | 7.00K | 337.0K | 165.7K | 422 | 734 | 1.54K | 23.5K | 27.4K |
| EBITDA | -26.5M | -20.4M | -15.5M | -8.09M | -6.48M | -2.77M | -2.20M | -2.20M | -1.45M | -1.20M |
| Interest expense | 177.0K | 50.9K | 985.3K | 23.0K | ||||||
| Income before tax | -24.7M | -20.6M | -15.9M | -11.3M | -15.5M | -1.58M | -2.20M | -1.70M | -1.24M | -1.49M |
| Income tax | 172.0K | 177.0K | 5.00K | -42.4K | -270.6K | -264.8K | ||||
| Net income | -24.9M | -20.6M | -15.9M | -11.3M | -15.5M | -1.58M | -1.94M | -1.70M | -1.24M | -1.49M |
| Earnings per share, basic | -1.70 | -2.16 | -2.21 | -3.81 | -7.73 | -0.58 | -0.71 | -4.84 | -3.51 | -4.23 |
| Earnings per share, diluted | -1.70 | -2.16 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 9.80M | 40.1M | 22.1M | 1.92M | 4.87M | 717.5K | 399.1K | 10.1K | 1.13M | 2.36M |
| Short-term investments | 17.9M | 8.47M | 17.5M | 2.36M | ||||||
| Receivables | 369.3K | 583.0K | 260.4K | 528.0K | 409.1K | 12.5K | 129.7K | 88.4K | 37.1K | |
| Inventory | -583.0K | -260.0K | -528.0K | -409.1K | ||||||
| Current assets | 31.9M | 50.7M | 40.3M | 2.23M | 5.44M | 1.13M | 1.07M | 175.0K | 1.37M | 2.42M |
| Property, plant and equipment | 5.00K | 4.00K | 13.8K | 5.85K | ||||||
| Goodwill | -190 | |||||||||
| Total assets | 31.9M | 50.7M | 44.3M | 6.20M | 12.6M | 1.13M | 1.07M | 178.1K | 1.37M | 2.45M |
| Accounts payable | 4.11M | 3.58M | 1.04M | 1.47M | 1.13M | 128.5K | 629.2K | |||
| Current liabilities | 4.11M | 3.58M | 3.62M | 2.83M | 2.10M | 220.0K | 664.8K | 802.5K | 288.2K | 138.1K |
| Total debt | 1.09M | |||||||||
| Total liabilities | 4.11M | 3.58M | 3.62M | 2.83M | 2.10M | 1.31M | 664.8K | 802.5K | 288.2K | 138.1K |
| Shareholders' equity | 27.8M | 47.2M | 40.7M | 3.37M | 10.5M | -183.8K | 408.6K | -624.4K | 1.09M | 2.31M |
| Shares outstanding | 14.6M | 7.20M | 2.97M | 2.01M | 2.74M | 2.74M | 351.9K | 351.9K | 351.9K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -23.6M | -18.3M | -14.4M | -5.64M | -5.03M | -1.66M | -1.92M | -1.10M | -1.33M |
| Capital spending | -6.00K | -4.00K | -18.0K | -3.00K | -7.25K | 0 | -771 | -3.19K | -4.03K |
| Free cash flow | -23.6M | -18.3M | -14.5M | -5.79M | -5.04M | -1.66M | -1.93M | -1.11M | -1.34M |
| Cash from investing | -9.42M | 4.66M | -17.5M | -3.00K | 1.74M | -771 | -3.19K | -4.03K | |
| Cash from financing | 2.24M | 37.6M | 51.0M | 2.77M | 7.45M | 1.98M | 1.16M | ||
| Dividends paid | 0 | 0 | |||||||
| Share buybacks | 2.24M | 37.0M | 2.02M | ||||||
| Change in cash | -30.3M | 23.4M | 20.1M | -2.95M | 4.15M | 318.4K | -767.9K | -1.12M | -366.5K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 6, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 27, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 21, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 24, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 15, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 9, 2026 | Current report | SEC |
All 56 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Sep 1, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Aug 14, 2026 | Current report | SEC |
| SUPPL | Aug 14, 2026 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Aug 13, 2026 | Current report | SEC |
| F-X | Aug 11, 2026 | Other filings | SEC |
| F-10 · Registration statement | Aug 11, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jul 8, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 29, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 25, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 17, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 17, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 27, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 20, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | May 15, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Apr 9, 2026 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2026 | Offer document | SEC |
| 40-F · Annual report | Mar 27, 2026 | Annual report | SEC |
| 6-K · Report of a foreign issuer | Mar 27, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Mar 10, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 24, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 19, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 18, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 17, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 10, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 6, 2026 | Current report | SEC |
| SUPPL | Feb 6, 2026 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Feb 6, 2026 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Feb 5, 2026 | Other filings | SEC |
| F-X | Feb 5, 2026 | Other filings | SEC |
| F-10 · Registration statement | Feb 5, 2026 | Offer document | SEC |
| D | Jan 3, 2025 | Other filings | SEC |
| D | May 25, 2023 | Other filings | SEC |
| D | Sep 27, 2022 | Other filings | SEC |
| D | Sep 10, 2019 | Other filings | SEC |
| D | Mar 8, 2019 | Other filings | SEC |
| D | Feb 5, 2014 | Other filings | SEC |
| D/A | Nov 21, 2013 | Other filings | SEC |
| D | Nov 15, 2011 | Other filings | SEC |
| D/A | Dec 1, 2009 | Other filings | SEC |
| D | Nov 6, 2009 | Other filings | SEC |
| REGDEX | Mar 25, 2009 | Other filings | SEC |
| REGDEX | Dec 19, 2007 | Other filings | SEC |
Cap table
Built by 6ix from Satellos Bioscience Inc’s releases · as of Feb 9, 2026
- Common shares
- 21,216,439
- Fully diluted
- 21,216,439
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 21,216,439 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 21,216,439 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adam Mostafa | Director | Chair, Audit Committee · Since at least Jun 18, 2025 |
| Antoinette Paone | Chief Development Officer and Head of Regulatory Affairs · Since at least Jan 29, 2026 |
| Brian Bloom | Director · Since at least Jun 18, 2025 |
| Caitlin Lowie | Vice President, Investor Relations & Communications · Since at least Oct 27, 2026 |
| Frank Gleeson | Co-founder, Chief Executive Officer, Board Director · Since at least Oct 5, 2026 |
| Franklin M. Berger | Director · Since at least Feb 9, 2026 |
| Geoff MacKay | Chair, BOD | Chair, Compensation Committee · Since at least Jun 18, 2025 |
| Iris Loew-Friedrich | Director · Since at least Jun 18, 2025 |
| Liz Williams | CFO · Since at least Mar 27, 2026 |
| Mark Nawacki | Director · Since at least Nov 14, 2025 |
All 13 people
| Person | Seat |
|---|---|
| Selwyn Ho | Director · Since at least Jun 18, 2025 |
| Stephanie Brown | Director | Chair, Nominations and Governance Committee · Since at least Jun 18, 2025 |
| Wildon Farwell | chief medical officer · Aug 13, 2025 – Nov 4, 2026 · Past |
Log in to ask 6ix AI your own questions about Satellos Bioscience Inc.